EGFR and non-small cell lung carcinoma: In the ADAURA trial, patients with stage IB–IIIA (AJCC 7th edition) NSCLC harboring EGFR exon 19 deletion or exon 21 L858R mutations who had undergone surgical resection were randomized to receive three years of osimertinib versus placebo.